Table 1. Demographic data and clinical characteristics of patients with Graves' disease and Hashimoto's thyroiditis.
| Gender | Age of diagnosis | Free T3 | Free T4 | TSH | TgAb positive | TPOAb positive | TRAb positive | ||
| Patients groups | (F:M) | (y) | (pg/mL) | (ng/dL) | (IU/L) | n (%)a | n (%)a | n (%)b | |
| Graves' disease | n | 95∶16 | 111 | 89 | 91 | 109 | 108 | 110 | 83 |
| 6∶1 | 44.47±16.11 | 3.86±2.67 | 1.67±1.74 | 1.38±4.49 | 98 (88.3) | 91 (82.7) | 34 (41.0) | ||
| Hashimoto's thyroiditis | n | 385∶35 | 420 | 418 | 420 | 393 | 410 | 411 | 404 |
| 11∶1 | 45.6±15.95 | 3.00±1.26 | 1.36±1.49 | 2.34±3.78 | 368 (89.8) | 298 (72.5) | 54 (13.4) |
Abbreviations: F, female; M, male; y, years. Data are expressed as mean ± standard deviation. n indicates the number of patients from whom we obtained clinical data and was different for each characteristic.
Until March 2009 the Siemens ADVIA Centaur CP immunoassay system was the applied assay for thyroid function tests (reference values: antithyroglobulin 0.0–0.60 IU/mL and antithyroid peroxidase 0.0–60.0 IU/mL); after that the laboratory changed to Abbot Architect i2000 (reference values: antithyroglobulin <4.11 IU/mL and antithyroid peroxidase <5.61 IU/mL). For this reason only quantitative assessment (positive/negative) was considered.
Positive serum TRAbs (>1.8 IU/L). All HT patients were submitted to thyroid hormone replacement therapy (levothyroxine).